Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins

European Journal of Haematology

Volumn 77, Issue 4, 2006, Pages 293-299

  Candoni, Anna ^a,c   Michelutti, Angela ^a   Simeone, Erica ^a   Damiani, Daniela ^a   Baccarani, Michele ^b   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Liposomal daunorubicin; Lymphoblastic leukaemia; Multidrug resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; ITRACONAZOLE; LEVOFLOXACIN; LIPOSOMAL DAUNORUBUCIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NYSTATIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; BACTEREMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG FORMULATION; EFFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYREXIA IDIOPATHICA; REMISSION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIPOSOMES; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RECURRENCE;

EID: 33748341281     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00708.x     Document Type: Article

References (43)

1. FADERL S, JEHA S, KANTARJIAN H. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003;98:1337-1354.
2. HOELZER D, GÖKBUGET N, OTTMANN O, PUI C, RELLING VM, APPELBAUM F, VAN DONGEN J, SZCZEPASKI T. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2002;162-192.
3. THOMAS D, KANTARJIAN H, SMITH T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Characteristics, treatment results and prognosis with salvage therapy. Cancer 1999;86:1216-1230.
4. DOMBRET H, GABERT J, BOIRON J-M, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 Trial. Blood 2002;100:2357-2366.
5. CHARRIN C. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Group Francais de Cytogénétique Hématologique. Blood 1996;87:3135-3142.
6. DAMIANI D, MICHELUTTI A, MICHIELI M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated proteins in de-novo adult acute lymphoblastic leukemia. Br J Haematol 2002;116:519-527.
7. TAFURI A, GREGORJ C, PETRUCCI MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974-981.
8. MICHIELI M, DAMIANI D, ERMACORA A, et al. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukemic blast cells. Br J Haematol 1997;96:356-365.
9. GÖKBUGET N, HOELZER D. The role of high-dose cytarabine in induction therapy for adult ALL. Leuk Res 2002;26:473-476.
10. WEISS MA, ALIFF TB, TALLMAN MS, FRANKEL SR, KALAYCIO ME, MASLAK PG, JURCIC JG, SCHEINBERG DA, ROMA TE. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002;95:581-587.
11. ALLEN TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998;56:747-756.
12. BACCARANI M, MICHIELI M, RUSSO D, et al. Liposomal daunorubicin (Daunoxome) in the treatment of acute leukemia. Blood 1999;94(Suppl. 1):508a.
13. RUSSO D, PICCALUGA PP, MICHIELI M, et al. Liposomal daunorubicin (Daunoxome) for treatment of poor-risk acute leukemia. Ann Haematol 2002;81:462-466.
14. PIERRI I, MIGLINO M, GATTO S, et al. Combination of liposomal daunorubicin (Daunoxome), fludarabina and cytarabine as salvage therapy in relapsed and refractory acute leukemia. Blood 2000;96:215b.
15. CORTES J, O'BRIEN S, ESTEY E, GILES F, KEATING M, KANTARJIAN H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999;17:81-87.
16. GILL PS, ESPINA BM, MUGGIA F, et al. Phase I/II clinical and pharmacokinetic evalutation of liposomal daunorubicin. J Clin Onco 1995;13:996-1003.
17. FORSSEN EA, COULTER DM, PROFFIT RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992;52:3255-3261.
18. GUAGLIANONE P, CHAN K, DELA FLOR-WEISS E, et al. Phase I and pharmacologic study of liposomal daunorubicin (Daunoxome). Invest New Drugs 1994;12:103-110.
19. RAHAMAN A, FUMAGALLI A, GOODMAN A, SCHEIN PS. Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 1994;11(Suppl. 3):45-55.
20. MICHIELI M, DAMIANI D, ERMACORA A, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol 1999;106:92-99.
21. MICHIELI M, DAMIANI D, ERMACORA A, MASOLINI P, MICHELUTTI A, BACCARANI M. Liposome-encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance. Haematologica 1999;84:1151-1152.
22. ERMACORA A, MICHIELI M, PEA F, VISANI G, BUCALOSSI A, RUSSO D. Liposomal daunorubicin (Daunoxome) for acute leukemia. Haematologica 2000;85:324-325.
23. DHOOGE C, DE MOERLOOSE B, LAUREYS G, KINT J, FERSTER A, DE BACQUER D, PHILIPPE J, BENOIT Y. P-glycoprotein is an indipendent prognostic factor predicting relapse in childhood acute lymphoblastic leukemia: results of a 6 year prospective study. Br J Haematol 1999;105:676-683.
24. SUVANNASANKHA A, MINDERMAN H, O'LOUGHIN K, NAKANISHI T, FORD LA, GRECO WR, WETZLER M, ROSS DD, BAER MR. Breast cancer resistance protein (BRCP/MXR/ABCG2) in adult lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004;127:392-398.
25. ELIAS L, SHAW MT, RAAB SO. Reinduction therapy for adult acute leukemia with adriamycin, vincristine, and prednisone: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:1413-1415.
26. GIONA F, ANNINO L, RONDELLI R, et al. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol 1997;97:896-903.
27. KOLLER CA, KANTARJIAN HM, THOMAS D, O'BRIEN S, RIOS MB, KORNBLAU S, MURPHY S, KEATING M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997;11:2039-2044.
28. YAP BS, MCCREDIE KB, KEATING MJ, BODEY GP, FREIREICH EJ. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 1981;65(Suppl. 1):83-87.
29. MARSH W, WOZNIAK A, MCCARLEY D. Therapy of relapsed acute lymphocytic leukemia: a 5 year experience with high dose Ara-C. Proc Am Soc Clin Oncol 1987;6:147.
30. ARLIN ZA, FELDMAN E, KEMPIN S, et al. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 1988;72:433-435.
31. SUKI S, KANTARJIAN H, GANDHI V, ESTEY E, O'BRIEN S, BERAN M, RIOS MB, PLUNKETT W, KEATING M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 1993;72:2155-2160.
32. MONTILLO M, TEDESCHI A, CENTURIONI R, LEONI P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma 1997;25:579-583.
33. WILES ME, BELL C. Anthracycline efficacy in vitro: cytotoxicity of liposomial/nonliposomial daunorubicin and doxorubicin for multiple tumor cell types. Drug Delive 1997;4:225-262.
34. TODESCHINI G, MENEGHINI V, PIZZOLO G, et al. Relationschip between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994;8:376-381.
35. PEREZ ATAYDE AR, SALLAN SE, TEDROW U, CONNORS S, ALLRED E, FOLKMAN J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-821.
36. FIELDER W, GRAEVEN U, ERGUN S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-1875.
37. PEA F, RUSSO D, MICHIELI M, DAMIANI D, FANIN R, MICHELUTTI A, MICHELUTTI T, PICCOLROVAZZI S, BACCARANI M, FURLANUT M. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukemia. Clin Pharmacokinet 2003;42:851-862.
38. PEA F, RUSSO D, MICHIELI M, et al. Liposomal-daunorubicin plasmatic and renal disposition in patients in patients with acute leukemia. Cancer Chemother Pharmacol 2000;46:279-286.
39. BELLOTT R, AUVRIGNON A, LEBLANC T, et al. Pharmacokinetics of liposomal daunorubicin (Daunoxome) during a phase I-II study in children with relapsed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001;47:15-21.
40. OFFIDANI M, CORVATTA L, CENTURIONI R, LEONI F, MALERBA L, MELE A, MARCONI M, SCORTECHINI A, MASIA MC, LEONI P. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. The Hematology Journal 2003;4:47-53.
41. KANTARJIAN H, O'BRIEN S, SMITH TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-561.
42. FASSAS A, BUFFELS R, ANAGNOSTOPOULOS A, GACOS E, VADIKOLIA C, HALOUDIS P, KALOYANNIDIS P. Safety and early efficacy assessment of liposomal daunorubicin (Daunoxome) in adults with refractory or relapsed acute myeloblastic leukemia: a phase I-II study. Br J Haematol 2002;116:308-315.
43. LIU F-T, KELSEY SM, NEWLAND AC, JIA L. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, deplection of ATP and necrotic cell death in human leukaemic cells. Br J Haematol 2002;117:333-342.